1806 – Marstacimab for routine prophylaxis to prevent bleeding in patients with haemophilia

Referral from the National Blood Authority.

Marstacimab is a human monoclonal antibody (immunoglobulin G isotype, subclass 1 [IgG1]) for children and adults aged 12 years and over with severe haemophilia A or severe haemophilia B, without inhibitors to FVIII or FIX. It is a once-weekly injection administered under the skin to help reduce the risk and/or severity of bleeding episodes experienced by people with haemophilia. 

Type: Therapeutic

Haemophilia is a congenital lifelong bleeding disorder caused by deficiency or dysfunction of clotting factor VIII (FVIII) or clotting factor IX (FIX). Haemophilia patients experience bleeding episodes due to reduced levels of factor concentrate.

The following consultation deadlines apply:

• Pre-PASC consultation deadline: Friday 11 July 2025 11:59pm AEDT
• Pre-MSAC consultation deadline: 

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: 15 August 2025
• ESC meeting: 
• MSAC meeting: 

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.